Forecast

There is no analyst data available for this company.

News Go to news feed

Egetis Therapeutics increases revenue and prepares US launch of Emcitate

Egetis Therapeutics reported a currency-adjusted revenue increase of 23% to SEK 17.4m in the second quarter and ended the quarter with SEK 378m in cash after a SEK 350m capital raise. Operating loss widened to SEK 109.3m as the company invested in the US approval process, building its sales organization and launch preparations. The FDA has accepted the approval application for Emcitate and set a PDUFA date of 28 September; if approved, a US launch is planned for Q4, prompting a positive reaction in the stock. » More on de.investing.com
Egetis Therapeutics could receive FDA priority review voucher if approved

Egetis Therapeutics would qualify for a Priority Review Voucher under the FDA’s Rare Pediatric Disease Priority Review Program if approved; the program has been extended through 2029. Such vouchers accelerate future approval processes or can be sold to other pharma companies, making them a valuable asset for the company. A voucher would strategically help Egetis in the development and commercialization of its therapies for rare pediatric diseases. » More on de.investing.com
Egetis Therapeutics falls despite positive Triac data after Q3 results

Egetis Therapeutics reported Q3 2025 revenue rising to SEK 17.4m (Q3 2024: SEK 9.4m) and an improved but still negative operating loss for the year of SEK -219.6m. The ReTRIEVE study showed positive, statistically significant results and Triac received Breakthrough Therapy Designation. After the earnings call the stock fell 4.49% to USD 5.11; the company bolstered liquidity via a rights issue of SEK 172m. Egetis plans to submit a rolling NDA for MCT8 deficiency in December 2025, with expected FDA review in Q3 2026 and target U.S. market launch in H2 2026. » More on de.investing.com

Financials

In the last quarter, Egetis Therapeutics had revenue of €1.57M and net profit of -€9.83M

(EUR)	Jun 2026	YoY
Revenue	1.57M	20.66%
Gross profit	324.85K	141.31%
Net profit	-9.83M	41.10%
EBITDA	-8.7M	30.10%

Fundamentals

Metric	Value
Market capitalization	€336.85M
Number of shares	464.95M
52-week high/low	€0.73 - €0.33
Dividends	No
Beta	0.78
P/E ratio	-7.96
PEG ratio	9.34
P/B ratio	7.50
P/S ratio	56.55

Company profile

Egetis Therapeutics AB (publ), ein Unternehmen der pharmazeutischen Arzneimittelentwicklung, konzentriert sich auf Projekte in der späten Entwicklungsphase zur Behandlung schwerer seltener Nischenkrankheiten mit ungedecktem medizinischem Bedarf im Bereich der Orphan Drugs. Die Produktpipeline des Unternehmens umfasst Aladote, ein Medikament zur Verringerung des Risikos akuter Leberschäden im Zusammenhang mit Acetaminophen/Paracetamol-Vergiftungen, das sich in der klinischen Phase IIb/III befindet, sowie Emcitate, ein Medikament zur Behandlung des MCT8-Mangels, einer seltenen angeborenen Störung der Schilddrüsenhormon-Signalübertragung, das sich in der klinischen Phase IIb/III befindet. Das Unternehmen war früher als PledPharma AB (publ) bekannt und änderte im Dezember 2020 seinen Namen in Egetis Therapeutics AB (publ). Egetis Therapeutics AB (publ) wurde im Jahr 2006 gegründet und hat seinen Sitz in Stockholm, Schweden.